GOLDSTEIN DOV A MD — SEC Form 4 filings
SEC reporting owner CIK 1120478. 15 Form 4 filings on record with FilingPulse; latest filed 2026-07-17.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-01-19 to 2026-07-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 4 legs across 1 filing — 27,000 shares, $531,828 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 21.
- Largest priced transaction: sale of 11,663 shares @ $20.54 ($239,549) in BioAge Labs, Inc., filed 2026-01-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | Chief Financial Officer | 7 | — | 4 legs · 27,000 sh · $531,828 | 12 |
| Coya Therapeutics, Inc. (COYA) | Director | 5 | — | — | 6 |
| Gain Therapeutics, Inc. (GANX) | Director | 3 | — | — | 3 |
Form 4 filings — GOLDSTEIN DOV A MD
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-17 | 4 | Gain Therapeutics, Inc. (GANX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-24 | 4 | BioAge Labs, Inc. (BIOA) | Option exercise (M): 3,542 @ $4.38 · Option exercise (M): 3,542 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | BioAge Labs, Inc. (BIOA) | Option exercise (M): 3,542 @ $4.38 · Option exercise (M): 3,542 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | BioAge Labs, Inc. (BIOA) | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | BioAge Labs, Inc. (BIOA) | Option exercise (M): 3,541 @ $4.38 · Option exercise (M): 3,541 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | BioAge Labs, Inc. (BIOA) | Option exercise (M): 3,542 @ $4.38 · Option exercise (M): 3,542 (derivative) @ $0 | EDGAR |
| 2026-01-15 | 4 | BioAge Labs, Inc. (BIOA) | Option exercise (M): 27,000 @ $8.39 · Sale (S): 8,974 @ $18.43 · Sale (S): 4,440 @ $19.45 · Sale (S): 11,663 @ $20.54 · Sale (S): 1,923 @ $21.08 · Option exercise (M): 27,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Coya Therapeutics, Inc. (COYA) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-08-19 | 4 | Coya Therapeutics, Inc. (COYA) | Option exercise (M): 17,557 @ $1.09 · Option exercise (M): 17,557 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | Gain Therapeutics, Inc. (GANX) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-02-25 | 4 | Coya Therapeutics, Inc. (COYA) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | BioAge Labs, Inc. (BIOA) | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Coya Therapeutics, Inc. (COYA) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2024-06-26 | 4 | Gain Therapeutics, Inc. (GANX) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Coya Therapeutics, Inc. (COYA) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1120478 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →